China Pharma Profit Rises 1.4% in First Half, Ups Interim Dividend 40%
SingTao · 2 SOURCESabout 3 hours ago2 MIN
Summary
China Sino Biopharma (HKEX: 1177) delivered solid first-half results for 2024, with profit climbing 1.4% year-on-year to 3.43 billion yuan despite a challenging pharmaceutical market. The company increased its interim dividend by 40% to 7 Hong Kong cents per share, rewarding shareholders while maintaining robust cash reserves. Innovation drugs and international licensing emerged as the company's second growth engine, with these segments now contributing nearly half of total revenue.
Key Points
- Profit attributable to shareholders rose 1.4% year-on-year to 3.43 billion yuan in the first half of 2024, with basic earnings per share increasing 1.5% to 19.1 fen .
- Total revenue grew 10.6% year-on-year to 19.44 billion yuan, driven by a 44.3% surge in innovation drug and licensing income to 8.79 billion yuan .
- The interim dividend was increased by 40% to 7 Hong Kong cents per share, reflecting strong cash generation and confidence in future performance .
- Cash reserves stood at approximately 34.58 billion yuan as of June 30, 2024, with net cash including wealth management products at 17.41 billion yuan .
- The company rebranded its English name to SBP Group, representing Science, Breakthroughs, and Patients, signaling a strategic push toward international expansion .
Why It Matters
Sino Biopharma's strong first-half performance demonstrates how Chinese pharmaceutical companies are successfully transitioning from generic drug manufacturers to innovation-driven enterprises. The company's plan to launch nearly 30 Class 1 innovative drugs between 2026 and 2030 positions Hong Kong investors to benefit from China's growing prominence in global biopharmaceutical development.
Sino Biopharma's strong first-half performance demonstrates how Chinese pharmaceutical companies are successfully transitioning from generic drug manufacturers to innovation-driven enterprises. The company's plan to launch nearly 30 Class 1 innovative drugs between 2026 and 2030 positions Hong Kong investors to benefit from China's growing prominence in global biopharmaceutical development.